Monoclonal Antibody Therapy for High Risk COVID Patients

Since their initial emergency authorization in November, monoclonal antibodies have been an important weapon in the fight against COVID-19. These products have proven to be effective at preventing hospitalization and death due to COVID-19 in some of the highest risk patients. This presentation will provide an overview of these products, the data behind their emergency authorization, and the clinical considerations around their use.